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Background: The magnetic albumin nanosphere (MAN), encapsulating maghemite nanopar-
ticles, was designed as a magnetic drug delivery system (MDDS) able to perform a variety of 
biomedical applications. It is noteworthy that MAN was efficient in treating Ehrlich’s tumors 
by the magnetohyperthermia procedure.
Methods and materials: In this study, several nanotoxicity tests were systematically carried 
out in mice from 30 minutes until 30 days after MAN injection to investigate their biocompat-
ibility status. Cytometry analysis, viability tests, micronucleus assay, and histological analysis 
were performed.
Results: Cytometry analysis and viability tests revealed MAN promotes only slight and temporary 
alterations in the frequency of both leukocyte populations and viable peritoneal cells, respectively. 
Micronucleus assay showed absolutely no genotoxicity or cytotoxicity effects and histological 
analysis showed no alterations or even nanoparticle clusters in several investigated organs but, 
interestingly, revealed the presence of MAN clusters in the central nervous system (CNS).
Conclusion: The results showed that MAN has desirable in vivo biocompatibility, presenting 
potential for use as a MDDS, especially in CNS disease therapy.
Keywords: nanotoxicity, nanoparticle, genotoxicity, cytotoxicity, brain
Introduction
The last four decades have been marked by huge interest in the development of drug 
delivery systems (DDS), with special emphasis on the design and fabrication of DDS 
for cancer treatment. In general, DDS are engineered to minimize drug degradation 
upon administration, prevent undesirable side effects, and sustain and/or increase the 
drug’s bioavailability in the targeted area.1–3
More recently, a new generation of DDS, which is in association with magnetic 
nanoparticles (MNPs), has become particularly interesting. A MNP-based DDS 
(MDDS) may not only present enhanced structural stability, tissue absorption, and 
targeting while reducing side effects,2,4 but also reveal specific properties of MNPs, 
including the potential to carry out hyperthermia5,6 and thermoablation of tumor cells, 
magnetic resonance imaging contrast enhancement, gene therapy, magnetic separa-
tion, and even offer the possibility of being site-guided or localized in a specific target 
tissue by external gradient of magnetic fields.7–9
Magnetohyperthermia is a particularly interesting application of MNPs: after bind-
ing to cancer cells, MNPs can be submitted to an external alternating magnetic field, 
promoting a mild increase in local temperature. This increase can cause the preferential 
destruction of cancer cells, with minor effects to neighboring normal cells,1 because International Journal of Nanomedicine 2011:6
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Figure 1 Transmission electron photomicrography of magnetic albumin nanospheres.
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tumor cells are less resistant to the sudden rise in temperature 
than the surrounding normal cells. Magnetohyperthermia is 
currently used to improve cancer treatments when used in 
combination with radiotherapy or chemotherapy.10
To be used as MDDS, as for instance in magnetohyper-
thermia protocols, the magnetic phase requires high magnetic 
susceptibility, as can be found in ionic magnetic fluid (MF) 
samples. However, the drawback to this approach is that 
ionic MF samples are not biocompatible materials. Indeed, 
appropriate surface functionalization of the suspended 
MNPs in MF samples is important to avoid particle cluster-
ing while promoting higher biocompatibility and extended 
circulation time.3,11 Protein polymeric-based templates, such 
as albumin, have been developed to produce biocompat-
ible nanocomposites for the engineering of DDS.12,13 An 
illustrative example is Abraxane® (Celgene Corp, Summit, 
NJ), an albumin-stabilized nanoparticulated formulation of 
paclitaxel, presenting higher antitumoral activity in patients 
with metastatic breast cancer while inducing minor side 
effects compared to the free drug.14
Taking all of these aspects into account, a recently devel-
oped MDDS is introduced and biologically tested in this 
study. To produce the new MDDS, maghemite nanoparticles, 
suspended as a stable ionic MF sample, were subsequently 
encapsulated within albumin-based nanospheres, from now 
on labeled magnetic albumin nanospheres (MAN). Bearing in 
mind that in vivo tests involving nanoparticulated systems rep-
resent a key aspect of current investigations in nanotoxicology, 
this study aims to evaluate the as-produced MAN using female 
Swiss mice as the animal model. The performance of MAN as 
a MDDS depends on its biocompatibility profile and biodistri-
bution parameters; these in turn depend to a great extent upon 
the interaction between the nanoparticulated system and cells. 
For these reasons, MAN–cell interaction was investigated in 
this study. In particular, MAN was evaluated with regard to 
its biocompatibility and biodistribution. The findings lead to 
the conclusion that MAN has good biocompatibility, presents 
enormous potential for use as a MDDS, and is able to be used 
in a variety of applications, including magnetohyperthermia 
and photodynamic therapy, as reported elsewhere.6,15
Materials and methods
chemicals
Eosin methylene blue (Wright and Giemsa formulations), 
trypan blue and cyclophosphamide, and fetal bovine serum 
(FBS) were purchased from Vetec Fine Chemistry Ltd (Rio 
de Janeiro, Brazil), Sigma-Aldrich Co (São Paulo, Brazil), 
and Sorali Biotechnology (São Paulo, Brazil), respectively. 
Davidson liquid was prepared by mixing 40 mL of glycerin, 
40 mL of 40% formaldehyde, 120 mL of 95% ethanol, and 
120 mL of distilled water. All other chemicals were of ana-
lytical grade and used without further purification.
Magnetic nanospheres
Maghemite (γ-Fe2O3) nanoparticles (NPs), suspended as low-pH 
ionic magnetic fluid containing 2.3 × 1017   particles/mL,16 
were   dispersed in aqueous medium containing bovine serum 
albumin (BSA) in order to produce the MAN sample, follow-
ing the protocol already described in the literature.17 MAN was 
prepared following the heat denaturation method at 100°C of 
an aqueous solution containing bovine serum albumin (BSA) 
under mechanical stirring at 13,000 rpm for 20 minutes. 
Then an aliquot of the ionic magnetic fluid sample contain-
ing maghemite nanoparticles was added to the BSA aque-
ous   solution. The synthesis of the ionic magnetic fluid was 
performed following the methodology described by Morais 
et al.18 Shortly afterwards, ionic magnetic fluid with maghemite 
NPs (γ-Fe2O3) was synthesized by the coprecipitation method 
of Fe(II) and Fe(III) salts with ammonium hydroxide. After 
removing the aqueous solution, nitric acid was added to the 
precipitate until pH 3 was reached.
Transmission electron microscopy showed that MAN 
and maghemite NPs presented an average diameter of 
73.0 ± 3.0 nm and 8.9 ± 0.1 nm, respectively, by analysis 
micrographs (Figure 1). The average diameter of MAN and 
maghemite NPs was obtained by computer analysis, using International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the program Image-Pro Plus 5.1 (MediaCybernetics, Inc, 
Bethesda, MD). The distribution of particles was achieved 
using the best fit log normal. The maghemite content in 
the MAN sample was about 25% in mass and about 7% 
in volume fraction. At this maghemite particle content the 
particle–particle interaction is quite effective and the mag-
netocrystalline anisotropy energy is around 1.119 eV .6
Animals
Female Swiss mice, aged 8–10 weeks and weighing 18–22 g, 
obtained from the animal facility of the University of São 
Paulo, were housed in plastic cages (3 or 6/cage) at room 
temperature (20°C ± 2°C), kept under a 12-hour light/dark 
cycle with lights on at 6 am and free access to food and water.
Experimental design
To perform the in vivo application, lyophilized MAN was 
dispersed in FBS to obtain an aqueous suspension containing 
5 mg MAN/mL (1.23 × 1014 MAN/mL). Mice were randomly 
allocated in groups that were intraperitoneally treated with 
a bolus dose of (1) 100 µL of MAN suspension (n = 6), 
(2) 100 µL of FBS (n = 3), or (3) received no treatment 
(n = 6). Groups 1 and 3 were used as control.
Biocompatibility evaluation of MAN was performed by 
(a) total and differential leukocyte counts; (b) viability assay 
of peritoneal leukocytes; (c) genotoxicity and cytotoxicity 
studies in bone marrow; and (d) histological analysis of 
the brain, liver, lungs, spleen, pancreas, heart, and kidneys. 
Tests a, b, and d were performed at 30 minutes, 6, 12, 24, 
and 48 hours, and 7, 15, and 30 days after treatment, whereas 
test c was carried out at 24 and 48 hours, 7, 15, and 30 days 
after MAN or FBS administration. Histological analyses 
were also used to evaluate the MAN biodistribution profile. 
For the genotoxicity and cytotoxicity studies, a positive 
control group (n = 6) with intraperitoneally administered 
cyclophosphamide was included.
The present animal research was approved by the Animal 
Ethics Committee of the Institute of Biological Sciences, 
University of Brasília, Brazil.
Total and differential leukocyte counts
An aliquot (20 µL) of blood, collected through cardiac 
puncture, was homogenized with 380 µL of Turk’s solu-
tion for 2 minutes, and total white blood cells were counted 
visually in a Neubauer chamber using a light microscope 
(Axiophot; Carl Zeiss AG, Oberkochen, Germany). For the 
differential leukocyte count,19 blood smears or peritoneal 
cells imprinted in glass slides were fixed in methanol for 
5 minutes, stained with Wright–Giemsa dye, and observed 
under light microscope (n = 500 cells).
cell viability assay
Immediately after animal death, viable cells were identified 
by exclusion of trypan blue dye, which penetrates into the 
cells with reduced vitality. For the assay, 10 mL of phos-
phate buffered saline (PBS), 4°C, pH 7.2, were injected into 
the peritoneal cavity. Subsequently, 8 mL of the peritoneal 
liquid were collected and centrifuged in a DynacTM centri-
fuge (Clay AdamsTM, NJ) at 160 g for 5 minutes. The pellet 
was resuspended in cold PBS and diluted (1:5) with trypan 
blue solution (0.4%). Viable cells (presenting bright yellow 
color) and dead cells (stained in blue color) were counted in 
a Neubauer chamber using a light microscope.
genotoxicity and cytotoxicity evaluations
Micronucleus (MN) assay and the frequency of polychro-
matic erythrocytes (%) were used to study MAN genotoxic-
ity and cytotoxicity, respectively. The assay was performed 
with bone marrow erythrocytes. The femur bone marrow 
was collected with 1 mL of FBS and the cells centrifuged 
(160 g for 5 minutes). Supernatant was discarded and 50 µL 
of FBS were added to the pellet. Subsequently, 10 µL of 
suspension were smeared on glass slides, fixed by methanol 
for 5 minutes, and stained with Giemsa dye. Under the light 
microscope, 4000 erythrocytes were counted – 2000 poly-
chromatic erythrocytes (PCE) and 2000 normochromatic 
erythrocytes (NCE) – while registering the number of MN 
found in each cell type. For the evaluation of the induced-
MAN cytotoxicity, the number of PCE and NCE was also 
registered when either of these two cell populations reached 
the value of 2000. As a positive control group, six mice were 
intraperitoneally treated with cyclophosphamide at 4 mg/kg 
and the bone marrow red cells analyzed after 24 hours.19
Histological analyses
Histological analyses were performed to assess MAN-
induced morphological effects and biodistribution aspects.20 
Brain, liver, lungs, spleen, pancreas, heart, and kidneys were 
surgically removed. Portions of these organs were fixed in 
Davidson liquid at 4°C overnight, dehydrated by alcohol, 
followed by the diaphanization process using xylene, and 
subsequently embedded in paraffin blocks. Tissue sections 
of 5 µm thickness were stained with hematoxylin-and eosin 
or by Perls’ reaction. The tissue morphology was observed 
under a light microscope and the photomicrographies taken 
by an AxioCam MRc (Carl Zeiss AG).International Journal of Nanomedicine 2011:6
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Figure 2 Effects of MAN administration on blood (A) and peritoneal (B) leukocytes as a function of time.
Notes: The data correspond to the means and to the standard deviation; *significant differences between CWT and MAN treatment by Tukey’s post-hoc test: P , 0.05.
Abbreviations: CWT, control group without treatment; WBC, global white blood cells; Lym, lymphocytes; Neu, neutrophils; Eos, eosinophils; Mon, monocytes; Mac, 
macrophages; Mas, mastocytes; MAN, magnetic albumin nanosphere.
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statistical analysis
Statistical analysis was carried out using Minitab® 15 
(Minitab Inc, State College, PA) software. Data were 
expressed as mean ± standard deviation (SD) and statistical 
significance was accepted at a level of P , 0.05. Normal 
distribution and homogeneity of data variances were verified 
by Shapiro–Wilk and Levene tests, respectively. Differences 
between the groups were investigated through analysis of 
variance (ANOVA), and Tukey’s post-hoc test was chosen 
to carry out 2-to-2 comparisons between the treatments.
Results
Total and differential leukocyte counts
No significant differences were observed between control 
groups (Groups 2 and 3). Thus, only data providing compari-
sons between Group 1 (MAN-treated) and control Group 3 
are shown in Figure 2. With regard to the blood samples, our 
data indicate that the MAN treatment causes only a small 
number of significant decreases in the eosinophil popula-
tion after 6 hours (P = 0.029), in neutrophils after 24 hours 
(P = 0.035), and in total number of both leukocytes (P = 0.042) 
and lymphocytes (P = 0.031) after 7 days (see Figure 2A). 
Some of the peritoneal cavity white cell populations also 
presented significant but temporary increases in neutrophil 
and eosinophil populations after MAN application, mainly 
up to 7 days after injection (see Figure 2B).
cell viability assay
A significant decrease was observed in the percentage of 
viable cells at 24 hours (57%) and 15 days (73%) after MAN 
administration (see Figure 3), compared to the control group 
(87%). No significant differences were observed between 
the control groups in the time window of our experiments.
genotoxicity and cytotoxicity studies
The analyses indicated that MAN induced no significant 
increase in micronucleus frequency in either polychromatic 
or normochromatic bone marrow erythrocytes (Table 1). 
Whereas the micronucleus frequency was never higher 
than 4.33 ± 2.94 (P = 0.261) after MAN treatment, the International Journal of Nanomedicine 2011:6
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Figure 3 Effects of MAN administration on the index of viable peritoneal cells as a function of time.
Note: *Significant differences between CWT and MAN treatment by Tukey’s post-hoc test: P , 0.05.
Abbreviations: CWT, control group without treatment; MAN, magnetic albumin nanosphere.
Table 1 Effects of MAN administration on micronucleus frequency 
and polychromatic cell index
Time Group MN-PCE MN-NCE % PCE
CWT 3.67 ± 1.03 2.00 ± 1.10 0.55 ± 0.06
Pc 36.50 ± 5.39* 3.50 ± 1.38 0.49 ± 0.07
24 h FBs 1.67 ± 2.08 3.33 ± 2.31 0.54 ± 0.02
MAN 4.33 ± 2.94 3.83 ± 2.14 0.49 ± 0.04
48 h FBs 3.00 ± 1.00 4.00 ± 0.00 0.55 ± 0.01
MAN 3.17 ± 1.72 4.50 ± 2.67 0.49 ± 0.04
7 d FBs 3.33 ± 0.58 1.33 ± 2.31 0.51 ± 0.01
MAN 4.17 ± 1.17 2.50 ± 0.84 0.49 ± 0.04
15 d FBs 4.67 ± 1.53 1.00 ± 1.00 0.51 ± 0.01
MAN 4.17 ± 0.41 2.17 ± 0.75 0.53 ± 0.03
30 d FBs 2.00 ± 1.00 2.00 ± 1.00 0.53 ± 0.05
MAN 2.50 ± 1.23 1.50 ± 1.05 0.52 ± 0.06
Note: *Significant difference between CWT and cyclophosphamide treatment (PC) 
by Tukey’s post-hoc test, with P , 0.005.
Abbreviations:  CWT,  control  group  without  treatment;  PC,  positive  control 
treated with cyclophosphamide; FBs, fetal bovine serum; MAN, magnetic albumin 
nanosphere;  MN-PcE,  micronucleated  polychromatic  erythrocytes;  MN-NcE, 
micronucleated normochromatic erythrocytes; % PcE, percentage of polychromatic 
erythrocytes.
AB
CD
Figure 4 Photomicrographies of cNs showing ferric pigment in animals treated 
with MAN. (A) Erythrocytes in capillary from cerebellum 12 hours after treatment; 
(B) cells from BBB 12 hours after treatment; (C) glial cell (arrow) next to neurons 
from brain 24 hours after MAN treatment; (D) neurons from brain with nanoparticle 
clusters in one of the polar regions (arrow) 30 days after treatment. (A and B) sections 
stained with hematoxylin and eosin; (C and D) sections stained by Perls’ method.
Abbreviations: Er, erythrocyte; P, pericyte; E, endothelial cell; MAN, magnetic 
albumin nanosphere; BBB, blood–brain barrier; cNs, central nervous system.
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  administration of   cyclophosphamide significantly increased 
this value to 36.50 ± 5.39 (P = 0.000), as expected while using 
this positive control. Furthermore, no significant change was 
observed in the % PCE after MAN administration (Table 1).
histological analysis
Observation of MNP clustering was carried out while ana-
lyzing the histological slides of the brain. MNP clusters 
were visualized as brown or blue pigment after hematoxylin 
and eosin or Perls’ staining, respectively. Clusters were 
first observed associated with erythrocytes (Figure 4A) of cere-
bral cortex capillaries, cerebellum, medulla, and also in areas 
of circumventricular organs (CVO). The highest   concentration 
of MNP clusters associated with the erythrocytes was detected 
at 12 hours and 7 days after treatment. The analyses clearly 
showed that MNPs crossed the blood–brain barrier (BBB) as 
shown in Figure 4B, following distribution among both glial 
(Figure 4C) and choroid plexus cells. Additionally, MNPs 
were also internalized by neurons (  Figure 4D), mainly in gran-
ule cells from the cerebellum. The highest content of MNP 
clusters in neurons was found 2 days after the MAN treatment, 
followed by a reduction in MNP content 30 days after MAN 
injection. Apparently the glial cells are of the cellular type 
that accumulated not only the highest content of MNPs but 
also kept the MNP clusters for the longest time period in our   
experiments.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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MAN did not promote any histological alteration in the 
brain, liver, spleen, kidneys, heart, and pancreas, although 
MNP clusters were found in the central nervous system 
(CNS). The diluent FBS induced thickening of alveolar septa 
in control animals, and thus this effect was more intense in 
the lungs of MAN-treated animals (data not shown).
Discussion
In this study, MAN with 73.0 ± 3.0 nm average diameter was 
considered biocompatible. This statement is based on the data 
showing no cytotoxic, genotoxic, or neurotoxic effects and 
only temporary alterations in both white cell populations (up 
to 7 days) and cell viability (up to 15 days after MAN applica-
tion). Interestingly, MAN was able to cross the BBB safely, 
with no observable neurotoxicity, suggesting its potential 
use as MDDS, especially while targeting the CNS, an event 
only possible for a small number of drugs.21
It has been shown that the physical–chemical character-
istics of MNPs, such as core-shell chemical composition, 
surface charge, and size, modulate MNP behavior in the 
biological environment.22–24 For instance, the surface coating 
of nano-sized material structures with non-opsonin serum 
proteins, such as albumin, represents a successful strategy to 
reduce recognition by the phagocytary mononuclear system 
cells,25,26 while presenting a negative charge in neutral pH and 
a hydrophilic surface. In this context, the temporary decrease 
in leukocytes in the animals’ blood was possibly due to their 
migration to the peritoneum or any other targeted organ, 
as would be expected from a pro-inflammatory reaction to 
foreign particles. Late migration, especially of neutrophils, 
indicates that the phagocytary mononuclear system cells 
take longer to recognize the injected MAN.27–29 Thus, the 
combination of negatively charged surface and hydrophilicity 
embodied by MAN helps prevent major drawbacks in regard 
to leukocyte counts.
Differential count of peritoneal leukocytes was per-
formed to check the possible occurrence of local inflam-
matory effects after the intraperitoneal administration of 
MAN. Significant differences were not observed in the 
most abundant peritoneal cell populations (macrophages 
and lymphocytes). However, some fluctuations in peritoneal 
cell populations related to the inflammatory response (neu-
trophils and eosinophils)19,30–32 were detected until 7 days, 
even after just one single injection of MAN, as observed 
  previously. These fluctuations in peritoneal cell viability may 
be associated with the particulate state of the intraperitone-
ally administered MNPs and the consequent responses of 
neutrophil and eosinophil populations. After phagocytosis of 
a relatively high quantity of MAN, neutrophils die, releasing 
MNPs in the peritoneal cavity while reducing the viability 
index observed at 24 hours. Due to the particulate state of 
these released MNPs, more neutrophils are recruited to the 
peritoneum, increasing the peritoneal cell viability observed 
at 48 hours and 7 days. These fluctuations in neutrophil 
populations probably occur until the total clearance of MNPs 
from the peritoneum. Further, death of eosinophils from 8 to 
12 days after migration to the peritoneum may explain, to a 
lesser degree, the decrease in cell viability at 15 days after 
the MAN treatment. The effects detected in cell viability 
were temporary and observed until 48 hours (neutrophil) 
or 7 days (eosinophil) after treatment, thus evidencing only 
a slight inflammatory process.
Strong evidence of MAN biocompatibility was obtained 
with the MN assay. Although micronuclei development may 
be associated with reactive oxygen species (ROS) induced by 
iron excess,23,33 in the present study, the MN assay showed no 
MAN effect on cell division or genotoxicity, differently from 
other samples based on magnetic nanoparticles.19,20,32 Also, 
the % PCE indicated that the MAN sample was not cytotoxic 
to the erythrocytic lineage in bone marrow.
MAN biodistribution and the possible induction of tissue 
alterations, such as inflammatory infiltration, thickening, and 
tissue necrosis were investigated through histological analy-
ses. We hypothesize that individual MNPs, released from 
MAN due to bleaching while in the organism, were used to 
build clusters, thus suggesting MNP targets. MNP clusters 
were not visualized in the spleen, liver, pancreas, kidneys, 
or heart, differently from the data previously observed after 
administration of several magnetic fluid samples.11,19,20,31 It 
should be noted that the absence of histological alteration in 
the analyzed organs is another signature of MAN biocom-
patibility. On the other hand, MNP clusters were observed 
in the nervous tissue, suggesting the high specificity of this 
new albumin-based magnetic nanomaterial to the CNS. 
Interestingly, although MNP clusters were observed in the 
CNS, no histological alteration was detected in this organ. 
Transmission electron microscopy (TEM) investigations 
showed further evidence for this observation,34 suggesting 
that MAN reduced neurotoxicity.
The composition of iron and albumin seems to be impor-
tant in understanding not only the observed MAN biocompat-
ibility but also the cellular uptake mechanisms responsible for 
passage of MAN through the BBB, dispersion to the nervous 
tissue, and internalization by several CNS cellular types. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1715
Biocompatibility of magnetic albumin nanospheres
The specificity of MAN to the CNS is in agreement with 
Bickel’s report,35 which emphasized that albumin presents 
selectivity to brain tissue in rats, in comparison to other 
organs such as the liver, heart, and lungs. Other reports36,37 
showed that polyethylene glycol-coated liposomes and poly-
meric nanoparticles, both based on bovine albumin, were able 
to cross the BBB. Data in the literature allow us to hypoth-
esize that the ability of MAN to cross the BBB is partially 
due to the interaction of albumin with lipidic membranes.38 
Transport could be mediated by specific receptors, such as 
gp60, which facilitate transcytosis through BBB endothelial 
cells by a tyrosine-kinase dependent pathway.39
Furthermore, changes in cell membrane permeability, 
induced by the presence of Fe3+ on the structure and function 
of the phospholipid bilayer,40 may help shed light on the abil-
ity of MAN to cross the BBB. The region of CVO,41 where the 
capillaries from BBB are more permeable to solutes, could 
also influence interactions between MAN and the CNS. When 
MAN reaches the CNS the initial targeted regions were very 
close to lateral ventricles and the CVO.
A number of reports showed that MNPs can enter the 
brain and cause tissue injury.42 Previous studies showed 
that high concentrations of anionic or cationic nanopar-
ticles (NPs) disrupted the BBB, whereas neutral NPs and 
low concentrations of anionic NPs had no effect on BBB 
  integrity.43 Further, interactions of ferric ions with phospho-
lipids of bilayers may lead to the disruption of the structure 
of cellular membrane44 and decrease the fluidity of neuronal 
membranes.45 The structural changes in membranes may 
lead to higher internalization of iron through changes in 
permeability. Thus, iron could interact with structures of 
neuronal cytoskeletons, acting on the axonal transport sys-
tem and on synapses. In our study, it was found that glial 
cells were the cellular type that accumulated the highest 
content of MNPs and kept them for the longest period. It is 
known that glial cells46 accumulate a high concentration of 
iron when there is an injury, but are rarely seen accumulat-
ing iron in normal conditions.47 Nevertheless, no alterations 
were detected in glial cells, even under TEM analysis,34 
thus suggesting that the MAN surface chemical–physical 
characteristics protect CNS structures from injuries and that 
the released iron is not enough to induce reactive oxygen 
species generation.48
The finding of MAN biocompatibility is an important 
milestone in nanotoxicity research as it can foster future 
studies related to biomedical applications of MAN-related 
materials. The observed capacity of MAN to cross the BBB 
with reduced neurotoxicity is extremely promising for 
targeting diseases related to the CNS, such as Parkinson’s 
disease, Alzheimer’s disease, and multiple sclerosis.7,49 In 
addition, the authors firmly believe that MAN represents 
a promising material vehicle to selectively destroy cancer 
cells,   including brain tumors, mainly because those cells 
overexpress a number of receptors to albumin.12,17 MAN 
can be loaded with different materials, with the purpose 
of either diagnosis or therapy,6,15 since albumin presents 
a number of reactive amino and carboxylic groups. The 
potential of MAN in tumor treatment using magneto-
hyperthermia or carrying sensitizers for photodynamic 
therapy has been recently shown by in vitro15,40 and in vivo6 
investigations.
Conclusion
It is concluded that the designed and investigated magnetic 
albumin nanosphere (MAN) represents a biocompatible and 
safe material. This affirmation is mainly based on the data 
presenting absolutely no cytotoxic and genotoxic effects, nor 
any morphological alterations while tested using an animal 
model. MAN induced some slight and transitory alterations 
in other nanotoxicity tests that do not interfere in its bio-
compatibility status. Actually, data revealed the importance 
of investigating nanomaterials for a longer time window 
because some biological responses may be reversed after a 
relatively long period of time, as observed in the viability 
tests. Finally, the presence of MNP clusters in the central 
nervous system evidences the high specificity of MAN in 
targeting the brain, suggesting its use as a new MDDS that 
is able to cross the BBB, with reduced neurotoxicity, and 
thus representing a promising material platform for therapy 
of brain-related diseases.
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